FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376642201> ?p ?o ?g. }

• W4376642201 endingPage "175628642311705" @default.
• W4376642201 startingPage "175628642311705" @default.
• W4376642201 abstract "Background: Several pharmacological pathways have revealed statin to have a positive role in patients with for intracranial aneurysms. However, prior studies regarding the association between statin use and patients’ outcomes after pipeline embolization device (PED) treatment were not completely supportive. Objectives: To investigate whether statin medication following PED treatment would improve the outcomes of intracranial aneurysm patients in a real-world setting. Design: A retrospective multicenter cohort study. Methods: Patients were selected from the PLUS registry study conducted from November 2014 to October 2019 across 14 centers in China. The population was divided into two groups: those who received statin medication after the PED treatment and those who did not receive statin medication after PED treatment. Study outcomes included angiographic evaluation of aneurysm occlusion, parent arteries stenosis, ischemic and hemorrhage complications, all-cause mortality, neurologic mortality, and functional outcome. Results: 1087 patients with 1168 intracranial aneurysms were eligible; 232 patients were in the statin user group and the other 855 were in the non-statin user group. For the statin user group versus the non-statin user group, no significant difference was found for the primary outcomes of complete occlusion of aneurysm (82.4% versus 84.2%; p = 0.697). Of the secondary outcomes, none had a significant difference including stenosis of parent arteries ≥ 50% (1.4% versus 2.3%; p = 0.739), total subarachnoid hemorrhage (0.9% versus 2.5%; p = 0.215), all-cause mortality (0.0% versus 1.9%; p = 0.204), neurologic mortality (0.0% versus 1.6%; p = 0.280), excellent (95.5% versus 97.2%; p = 0.877), and favorable (98.9% versus 98.4%; p = 0.933) functional outcomes. The total ischemic complication rate (9.0% versus 7.1%; p = 0.401) was higher but not significant in the statin user group. The propensity score-matched cohort showed similar results. Results of binary multivariable logistic regression analysis and propensity score-matched analysis both showed that statin usage was not independently associated with an increased rate of complete occlusion or any other secondary outcomes. Subgroup analysis found the same result in patients who did not use statin before the procedure. Conclusion: Among patients with intracranial aneurysms, statin use after the PED treatment was not significantly associated with better angiographic and clinical outcomes. Well-designed studies are needed to further confirm this finding." @default.
• W4376642201 created "2023-05-17" @default.
• W4376642201 creator A5000769157 @default.
• W4376642201 creator A5001731025 @default.
• W4376642201 creator A5003642180 @default.
• W4376642201 creator A5012996466 @default.
• W4376642201 creator A5026924268 @default.
• W4376642201 creator A5028434850 @default.
• W4376642201 creator A5032786004 @default.
• W4376642201 creator A5035281991 @default.
• W4376642201 creator A5037000851 @default.
• W4376642201 creator A5040179399 @default.
• W4376642201 creator A5043966917 @default.
• W4376642201 creator A5051090513 @default.
• W4376642201 creator A5052931988 @default.
• W4376642201 creator A5055349222 @default.
• W4376642201 creator A5060985903 @default.
• W4376642201 creator A5062757899 @default.
• W4376642201 creator A5006570740 @default.
• W4376642201 date "2023-01-01" @default.
• W4376642201 modified "2023-10-17" @default.
• W4376642201 title "Could statin improve outcomes after pipeline embolization for intracranial aneurysms in a real-world setting?" @default.
• W4376642201 cites W2007101617 @default.
• W4376642201 cites W2010062608 @default.
• W4376642201 cites W2039944972 @default.
• W4376642201 cites W2059487790 @default.
• W4376642201 cites W2066687194 @default.
• W4376642201 cites W2071745239 @default.
• W4376642201 cites W2076834039 @default.
• W4376642201 cites W2085728170 @default.
• W4376642201 cites W2111635289 @default.
• W4376642201 cites W2136410856 @default.
• W4376642201 cites W2161821089 @default.
• W4376642201 cites W2164363487 @default.
• W4376642201 cites W2253702257 @default.
• W4376642201 cites W2345613317 @default.
• W4376642201 cites W2584152519 @default.
• W4376642201 cites W2825414563 @default.
• W4376642201 cites W2888013481 @default.
• W4376642201 cites W2898998405 @default.
• W4376642201 cites W2900037073 @default.
• W4376642201 cites W2900354984 @default.
• W4376642201 cites W2904114211 @default.
• W4376642201 cites W2905331745 @default.
• W4376642201 cites W2909249787 @default.
• W4376642201 cites W2946340114 @default.
• W4376642201 cites W2988991070 @default.
• W4376642201 cites W2996410020 @default.
• W4376642201 cites W3028594750 @default.
• W4376642201 cites W3095633442 @default.
• W4376642201 cites W3116512851 @default.
• W4376642201 cites W3120215063 @default.
• W4376642201 cites W3165215133 @default.
• W4376642201 cites W3216299442 @default.
• W4376642201 cites W4200368846 @default.
• W4376642201 cites W4280505775 @default.
• W4376642201 cites W4296713832 @default.
• W4376642201 doi "https://doi.org/10.1177/17562864231170517" @default.
• W4376642201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37187463" @default.
• W4376642201 hasPublicationYear "2023" @default.
• W4376642201 type Work @default.
• W4376642201 citedByCount "0" @default.
• W4376642201 crossrefType "journal-article" @default.
• W4376642201 hasAuthorship W4376642201A5000769157 @default.
• W4376642201 hasAuthorship W4376642201A5001731025 @default.
• W4376642201 hasAuthorship W4376642201A5003642180 @default.
• W4376642201 hasAuthorship W4376642201A5006570740 @default.
• W4376642201 hasAuthorship W4376642201A5012996466 @default.
• W4376642201 hasAuthorship W4376642201A5026924268 @default.
• W4376642201 hasAuthorship W4376642201A5028434850 @default.
• W4376642201 hasAuthorship W4376642201A5032786004 @default.
• W4376642201 hasAuthorship W4376642201A5035281991 @default.
• W4376642201 hasAuthorship W4376642201A5037000851 @default.
• W4376642201 hasAuthorship W4376642201A5040179399 @default.
• W4376642201 hasAuthorship W4376642201A5043966917 @default.
• W4376642201 hasAuthorship W4376642201A5051090513 @default.
• W4376642201 hasAuthorship W4376642201A5052931988 @default.
• W4376642201 hasAuthorship W4376642201A5055349222 @default.
• W4376642201 hasAuthorship W4376642201A5060985903 @default.
• W4376642201 hasAuthorship W4376642201A5062757899 @default.
• W4376642201 hasBestOaLocation W43766422011 @default.
• W4376642201 hasConcept C126322002 @default.
• W4376642201 hasConcept C141071460 @default.
• W4376642201 hasConcept C167135981 @default.
• W4376642201 hasConcept C2776035437 @default.
• W4376642201 hasConcept C2776098176 @default.
• W4376642201 hasConcept C2776839432 @default.
• W4376642201 hasConcept C2777736543 @default.
• W4376642201 hasConcept C2780007028 @default.
• W4376642201 hasConcept C2908647359 @default.
• W4376642201 hasConcept C71924100 @default.
• W4376642201 hasConcept C99454951 @default.
• W4376642201 hasConceptScore W4376642201C126322002 @default.
• W4376642201 hasConceptScore W4376642201C141071460 @default.
• W4376642201 hasConceptScore W4376642201C167135981 @default.
• W4376642201 hasConceptScore W4376642201C2776035437 @default.
• W4376642201 hasConceptScore W4376642201C2776098176 @default.
• W4376642201 hasConceptScore W4376642201C2776839432 @default.

• next